Tranzyme Pharma Secures Additional $9.3 Million Debt Financing

Tranzyme Pharma

today announced that it received an additional net $9.3 million in term loan proceeds through an amendment and restatement of its existing debt financing facility with Oxford Finance LLC and Horizon Technology Finance Corporation

. "We expect to file the NDA for our intravenous drug, ulimorelin, during Q4 2012, and have top-line Phase 2b data for our oral drug, TZP-102, by the end of 2012," said Vipin K. Garg, Ph.D., President and CEO of Tranzyme. "Based on our current operating plan, we anticipate this financing will extend our cash runway into Q4 2013, and provide us additional flexibility to meet our strategic objectives."